NIKKEI 225
38,102.44 -712.12 (-1.83%) HANG SENG
17,936.12 -5.66 (-0.03%) CRUDE OIL
79.85 +1.40 (+1.78%) GOLD FUTURES
2,329.70 -19.40 (-0.83%) DOW
38,742.02 +152.86 (+0.40%) Bitcoin GBP
52,207.47 -187.06 (-0.36%)
PRQR Jul 2024 2.500 call
| Previous close | 0.1200 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1200 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 672 |
Simply Wall St.Shareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years ago
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
GlobeNewswireProQR Announces First Quarter 2024 Operating and Financial Results
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General Meeting scheduled for May 22, 2024Continued strength of leading IP estate around ADAR-mediated RNA editing highlighted with successful defense of challenge to granted patent in Europe€102.7 million as of end of Q1 providing runway into mid
- GlobeNewswire
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’s AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasda
